Association of Opioid Use Disorder Treatment With Alcohol-Related Acute Events.
- Authors
- Xu, Kevin Y; Presnall, Ned; Mintz, Carrie M; Borodovsky, Jacob T; Bhat, Nisha R; Bierut, Laura J; Grucza, Richard A
- Year
- 2021
- Journal
- JAMA network open
- PMID
- 33625511
- DOI
- 10.1001/jamanetworkopen.2021.0061
- PMCID
- PMC7905500
IMPORTANCE: Persons with opioid use disorder (OUD) and co-occurring alcohol use disorder (AUD) are understudied and undertreated. It is unknown whether the use of medications to treat OUD is associated with reduced risk of alcohol-related morbidity. OBJECTIVE: To determine whether the use of OUD medications is associated with decreased risk for alcohol-related falls, injuries, and poisonings in persons with OUD with and without co-occurring AUD. DESIGN, SETTING, AND PARTICIPANTS: This recurrent-event, case-control, cohort study used prescription claims from IBM MarketScan insurance databases from January 1, 2006, to December 31, 2016. The sample included persons aged 12 to 64 years in the US with an OUD diagnosis and taking OUD medication who had at least 1 alcohol-related admission. The unit of observation was person-day. Data analysis was performed from June 26 through September 28, 2020. EXPOSURES: Days of active OUD medication prescriptions, with either agonist (ie, buprenorphine or methadone) or antagonist (ie, oral or extended-release naltrexone) treatments compared with days without OUD prescriptions. MAIN OUTCOMES AND MEASURES: The primary outcome was admission for any acute alcohol-related event defined by International Classification of Diseases, Ninth Revision and International Statistical Classification of Diseases and Related Health Problems, Tenth Revision codes. Conditional logistic regression was used to compare OUD medication use between days with and without an alcohol-related event. Stratified analyses were conducted between patients with OUD with and without a recent AUD diagnostic code. RESULTS: There were 8β―424β―214 person-days of observation time among 13β―335 participants who received OUD medications and experienced an alcohol-related admission (mean [SD] age, 33.1 [13.1] years; 5884 female participants [44.1%]). Agonist treatments (buprenorphine and methadone) were associated with reductions in the odds of any alcohol-related acute event compared with nontreatment days, with a 43% reduction for buprenorphine (odds ratio [OR],β0.57; 95% CI, 0.52-0.61) and a 66% reduction for methadone (OR, 0.34; 95% CI, 0.26-0.45). The antagonist treatment naltrexone was associated with reductions in alcohol-related acute events compared with nonmedication days, with a 37% reduction for extended-release naltrexone (OR, 0.63; 95% CI, 0.52-0.76) and a 16% reduction for oral naltrexone (OR, 0.84; 95% CI, 0.76-0.93). Naltrexone use was more prevalent among patients with OUD with recent AUD claims than their peers without AUD claims. CONCLUSIONS AND RELEVANCE: These findings suggest that OUD medication is associated with fewer admissions for alcohol-related acute events in patients with OUD with co-occurring AUD.
Flowchart for Development of Analytical SampleChart shows derivation of the studyβs final analytical sample during follow-up. After application of inclusion and exclusion criteria, there were 13 335 unique patients with opioid use disorder (OUD), all of whom had received OUD medication during insurance enrollment. The analytical sample was subsequently restricted to observations within 1 year before and 1 year after index alcohol-related acute event to decrease heterogeneity in observation time, contributing a total of 8 424 214 person-days in the study database.
Adjusted Odds of Alcohol-Related Acute Events Associated With Opioid Use Disorder (OUD) Treatment Days Compared With Nontreatment DaysPlot shows adjusted odds of alcohol-related acute events associated with OUD treatment days compared with nontreatment days, stratified for all participants, patients with OUD with recent alcohol use disorder (AUD) claims, and patients with OUD without recent AUD claims.
No entities extracted from this document yet.
No uploaded files.
| Citation | PMID | DOI | Status |
|---|---|---|---|
| Ahmad FB, Rossen LM, Sutton P; National Center for Health Statistics Provisional drug overdose death counts. Published 2020 Accessed January 21, 2021. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm | β | β | β |
| Allison P, Christakis N Fixed-effects methods for the analysis of nonrepeated events. Sociol Methodol. 2006;36(1):155-172. doi:10.1111/j.1467-9531.2006.00177.x | β | β | β |
| Caputo F, Addolorato G, Domenicali M, ; Services for Addiction Treatment Short-term methadone administration reduces alcohol consumption in non-alcoholic heroin addicts. Alcohol Alcohol. 2002;37(2):164-168. doi:10.1093/alcalc/37.2.16411912072 | β | β | β |
| Castle IJ, Dong C, Haughwout SP, White AM Emergency department visits for adverse drug reactions involving alcohol: United States, 2005 to 2011. Alcohol Clin Exp Res. 2016;40(9):1913-1925. doi:10.1111/acer.1316727488763PMC5008983 | β | β | β |
| Centers for Disease Control and Prevention Alcohol-related disease impact (ARDI) application. Updated September 3, 2020 Accessed January 21, 2021. https://nccd.cdc.gov/DPH_ARDI/default/default.aspx | β | β | β |
| Centers for Disease Control and Prevention, National Center for Health Statistics FactStats: accidents or unintentional injuries. Updated November 13, 2020 Accessed January 21, 2021. https://www.cdc.gov/nchs/fastats/accidental-injury.htm | β | β | β |
| Cicero TJ, Ellis MS, Kasper ZA Polysubstance use: a broader understanding of substance use during the opioid crisis. Am J Public Health. 2020;110(2):244-250. doi:10.2105/AJPH.2019.30541231855487PMC6951387 | β | β | β |
| Coffin PO, Galea S, Ahern J, Leon AC, Vlahov D, Tardiff K Opiates, cocaine and alcohol combinations in accidental drug overdose deaths in New York City, 1990-98. Addiction. 2003;98(6):739-747. doi:10.1046/j.1360-0443.2003.00376.x12780362 | β | β | β |
| Degenhardt L, Grebely J, Stone J, Global patterns of opioid use and dependence: harms to populations, interventions, and future action. Lancet. 2019;394(10208):1560-1579. doi:10.1016/S0140-6736(19)32229-931657732PMC7068135 | β | β | β |
| Dong H, Hayashi K, Milloy MJ, Changes in substance use in relation to opioid agonist therapy among people who use drugs in a Canadian setting. Drug Alcohol Depend. 2020;212:108005. doi:10.1016/j.drugalcdep.2020.10800532370932PMC7462099 | β | β | β |
| Dugosh K, Abraham A, Seymour B, McLoyd K, Chalk M, Festinger D A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction. J Addict Med. 2016;10(2):93-103. doi:10.1097/ADM.000000000000019326808307PMC4795974 | β | β | β |
| Frank D, Mateu-Gelabert P, Guarino H, High risk and little knowledge: overdose experiences and knowledge among young adult nonmedical prescription opioid users. Int J Drug Policy. 2015;26(1):84-91. doi:10.1016/j.drugpo.2014.07.01325151334PMC4277710 | β | β | β |
| Gomes T, Khuu W, Martins D, Contributions of prescribed and non-prescribed opioids to opioid related deaths: population based cohort study in Ontario, Canada. BMJ. 2018;362:k3207. doi:10.1136/bmj.k320730158106PMC6113771 | β | β | β |
| Hallas J, PottegΓ₯rd A, Wang S, Schneeweiss S, Gagne JJ Persistent user bias in case-crossover studies in pharmacoepidemiology. Am J Epidemiol. 2016;184(10):761-769. doi:10.1093/aje/kww07927780801 | β | β | β |
| Hassan AN, Le Foll B Polydrug use disorders in individuals with opioid use disorder. Drug Alcohol Depend. 2019;198:28-33. doi:10.1016/j.drugalcdep.2019.01.03130877954 | β | β | β |
| Hickman M, Lingford-Hughes A, Bailey C, Macleod J, Nutt D, Henderson G Does alcohol increase the risk of overdose death: the need for a translational approach. Addiction. 2008;103(7):1060-1062. doi:10.1111/j.1360-0443.2008.02134.x18397360 | β | β | β |
| Hser YI, Mooney LJ, Saxon AJ, High mortality among patients with opioid use disorder in a large healthcare system. J Addict Med. 2017;11(4):315-319. doi:10.1097/ADM.000000000000031228426439PMC5930020 | β | β | β |
| Jensen AK, Gerds TA, Weeke P, Torp-Pedersen C, Andersen PK On the validity of the case-time-control design for autocorrelated exposure histories. Epidemiology. 2014;25(1):110-113. doi:10.1097/EDE.000000000000000124257508 | β | β | β |
| Jones CM, McCance-Katz EF Co-occurring substance use and mental disorders among adults with opioid use disorder. Drug Alcohol Depend. 2019;197:78-82. doi:10.1016/j.drugalcdep.2018.12.03030784952 | β | β | β |
| Kinsky S, Houck PR, Mayes K, Loveland D, Daley D, Schuster JM A comparison of adherence, outcomes, and costs among opioid use disorder Medicaid patients treated with buprenorphine and methadone: a view from the payer perspective. J Subst Abuse Treat. 2019;104:15-21. doi:10.1016/j.jsat.2019.05.01531370980 | β | β | β |
| Mintz CM, Presnall NJ, Sahrmann JM, Age disparities in six-month treatment retention for opioid use disorder. Drug Alcohol Depend. 2020;213:108130. doi:10.1016/j.drugalcdep.2020.10813032593972PMC7903941 | β | β | β |
| Mittleman MA, Mostofsky E Exchangeability in the case-crossover design. Int J Epidemiol. 2014;43(5):1645-1655. doi:10.1093/ije/dyu08124756878PMC4190513 | β | β | β |
| Morgan JR, Schackman BR, Weinstein ZM, Walley AY, Linas BP Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort. Drug Alcohol Depend. 2019;200:34-39. doi:10.1016/j.drugalcdep.2019.02.03131082666PMC6613830 | β | β | β |
| Soyka M Alcohol use disorders in opioid maintenance therapy: prevalence, clinical correlates and treatment. Eur Addict Res. 2015;21(2):78-87. doi:10.1159/00036323225413371 | β | β | β |
| Srivastava A, Kahan M, Ross S The effect of methadone maintenance treatment on alcohol consumption: a systematic review. J Subst Abuse Treat. 2008;34(2):215-223. doi:10.1016/j.jsat.2007.04.00117596906 | β | β | β |
| Wang L, Min JE, Krebs E, Polydrug use and its association with drug treatment outcomes among primary heroin, methamphetamine, and cocaine users. Int J Drug Policy. 2017;49:32-40. doi:10.1016/j.drugpo.2017.07.00928888099PMC5681890 | β | β | β |
| Wang SV, Gagne JJ, Glynn RJ, Schneeweiss S Case-crossover studies of therapeutics: design approaches to addressing time-varying prognosis in elderly populations. Epidemiology. 2013;24(3):375-378. doi:10.1097/EDE.0b013e31828ac9cb23466528PMC6092740 | β | β | β |
| White JM, Irvine RJ Mechanisms of fatal opioid overdose. Addiction. 1999;94(7):961-972. doi:10.1046/j.1360-0443.1999.9479612.x10707430 | β | β | β |
| Winstanley EL, Stover AN, Feinberg J Concurrent alcohol and opioid use among harm reduction clients. Addict Behav. 2020;100:106027. doi:10.1016/j.addbeh.2019.06.01631683186PMC7147822 | β | β | β |
| Witkiewitz K, Vowles KE Alcohol and opioid use, co-use, and chronic pain in the context of the opioid epidemic: a critical review. Alcohol Clin Exp Res. 2018;42(3):478-488. doi:10.1111/acer.1359429314075PMC5832605 | β | β | β |
No papers in this knowledge base cite this source.
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Efficacy of Screening and Brief Intervention for Alcohol Misuse in Opioid Agonist Maintenance Treatment: A Randomized Clinical Trial. | Gupta S et al. | β | 2026 | β |
| Variation in initiation of medications for alcohol use disorder during alcohol withdrawal hospitalizations in a large health system: A retrospective cohort study. | Bernstein EY et al. | β | 2026 | β |
| Subtypes and service utilization among opioid use disorder patients at a community health center: findings from a medically underserved urban area of the Northeastern United States. | Ware OD et al. | β | 2025 | β |
| Use and Outcomes of Medication for Opioid Use Disorder Among Patients With Opioid Use Disorder Undergoing Surgery. | Li AH et al. | β | 2025 | β |
| Associations Between a Primary Care-Delivered Alcohol-Related Brief Intervention and Subsequent Opioid-Related Outcomes. | Blalock DV et al. | β | 2024 | β |
| Disrupted brain state dynamics in opioid and alcohol use disorder: attenuation by nicotine use. | Zhang R et al. | β | 2024 | β |
| Pregnancy Rates Among Women Treated with Medication for Opioid Use Disorder. | Bello JK et al. | β | 2024 | β |
| Prescription psychostimulant use, admissions and treatment initiation and retention in pregnant people with opioid use disorder. | Xu KY et al. | β | 2024 | β |
| Cessation of self-reported opioid use and impacts on co-occurring health conditions. | Scheidell JD et al. | β | 2023 | β |
| Concurrent opioid and alcohol withdrawal management. | Colvard M | β | 2023 | β |
| Improvements in recovery capital are associated with decreased alcohol use in a primary opioid use disorder treatment-seeking cohort. | Bormann NL et al. | β | 2023 | β |
| Alcohol Use. | Donroe JH et al. | β | 2022 | β |
| Analysis of Stimulant Prescriptions and Drug-Related Poisoning Risk Among Persons Receiving Buprenorphine Treatment for Opioid Use Disorder. | Mintz CM et al. | β | 2022 | β |
| Association of Bupropion, Naltrexone, and Opioid Agonist Treatment With Stimulant-Related Admissions Among People With Opioid Use Disorder: A Case-Crossover Analysis. | Xu KY et al. | β | 2022 | β |
| Factor Structure of the Brief Addiction Monitor in a Non-Veteran Substance Use Disorder Outpatient Treatment Sample. | Schumm J et al. | β | 2022 | β |
| Post-Combat-Injury Opioid Prescription and Alcohol Use Disorder in the Military. | Alcover KC et al. | β | 2022 | β |
| An examination between treatment type and treatment retention in persons with opioid and co-occurring alcohol use disorders. | Mintz CM et al. | β | 2021 | β |